07:48 AM EDT, 06/14/2024 (MT Newswires) -- BeiGene ( BGNE ) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma showed "promising efficacy and tolerability."

The company said the overall response rate among the 65 response-evaluable patients treated with the combination was 100%, and the rate of complete response plus complete response with incomplete hematopoietic recovery was 48%.

BeiGene ( BGNE ) also said the safety profile of the combination is consistent with that of the treatment components, and no new safety signals were seen.